Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech clinical trial

Ivonescimab HARMONi-2 Overall Survival Win vs Pembrolizumab

Analysis based on 9 articles · First reported Jul 20, 2026 · Last updated Sep 13, 2026

Sentiment
25
Attention
4
Articles
9
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The positive OS data strengthen ivonescimab's competitive position against pembrolizumab, Merck & Co.'s blockbuster Keytruda, potentially pressuring Merck's oncology franchise in first-line PD-L1-positive NSCLC while boosting Akeso's pipeline value and licensing prospects. Broader market impact is limited to the oncology and biotech sectors, with Akeso shares likely to react positively and Merck shares facing modest sentiment headwinds.

pharmaceuticals biotechnology oncology

Akeso announced that a pre-specified interim analysis of overall survival (OS) in the Phase III HARMONi-2 (AK112-303) trial, assessed by the Independent Data Monitoring Committee, met the key secondary OS endpoint. Ivonescimab, Akeso's first-in-class PD-1/VEGF bispecific antibody, demonstrated statistically significant and clinically meaningful improvement over pembrolizumab as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer whose tumors express PD-L1 (TPS >=1%). At the 2026 World Conference on Lung Cancer organized by the International Association for the Study of Lung Cancer, full OS data were published on the conference website on September 13, 2026, with a formal oral presentation scheduled for September 15 by Principal Investigator Caicun Zhou, IASLC President and Director of Oncology at Shanghai East Hospital. As of the August 20, 2026 data cutoff, median follow-up was 36 months with 234 OS events. In the intention-to-treat population, median OS was 30.8 months with ivonescimab versus 22.6 months with pembrolizumab (HR=0.73; 95% CI 0.57-0.95; P=0.009), a 27% reduction in risk of death. Benefit was consistent across subgroups, with a 42% reduction in risk of death in the PD-L1 TPS >=50% population (HR=0.58). No new safety signals emerged, and no apparent increase in bleeding risk was observed in high-risk squamous patients, a population traditionally contraindicated for anti-VEGF therapies. In May 2024 the trial had already met its primary progression-free survival endpoint (11.14 vs 5.82 months; HR=0.51), and the indication received regulatory approval in China in 2025. HARMONi-2 is the first randomized, double-blind, controlled Phase III study to show statistically significant positive OS and PFS results versus pembrolizumab. Akeso CEO Xia Yu (actor) highlighted the growing body of evidence supporting ivonescimab across solid tumors.

95 Akeso met overall survival endpoint
85 Akeso presented overall survival results
60 Akeso met progression-free survival endpoint
55 China approved ivonescimab indication Akeso
25 Caicun Zhou delivered oral presentation
stock
Akeso is the sponsor and primary beneficiary of the HARMONi-2 trial; the positive OS results reinforce ivonescimab's best-in-class potential and support its commercial and licensing outlook.
Importance 100.0 Sentiment 70.0
stock
Merck's pembrolizumab (Keytruda) is the comparator that ivonescimab beat on both OS and PFS, a competitive threat to its first-line NSCLC franchise.
Importance 70.0 Sentiment -25.0
cnt
China approved the ivonescimab indication in 2025, and the new OS data support continued domestic commercialization and regulatory standing.
Importance 40.0 Sentiment 10.0
per
Caicun Zhou is the HARMONi-2 principal investigator and IASLC President who will deliver the formal oral presentation of the complete OS results on September 15, 2026.
Importance 35.0 Sentiment 5.0
ngo
The IASLC organized the 2026 World Conference on Lung Cancer where the HARMONi-2 OS data were published and presented as a late-breaking abstract.
Importance 30.0 Sentiment 5.0
per
Xia Yu (actor), Akeso's Founder, Chairwoman, President and CEO, publicly framed the OS results as reinforcing ivonescimab's clinical value and broader solid-tumor potential.
Importance 30.0 Sentiment 5.0
oth
Shanghai East Hospital is the affiliation of principal investigator Caicun Zhou, lending clinical credibility to the trial results.
Importance 20.0 Sentiment 5.0
Merck & Co. related ↔ China
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.